FINWIRES · TerminalLIVE
FINWIRES

欧州投資銀行、EUのエネルギー転換を促進するため117億ドルの融資計画を発表

By

-- 欧州投資銀行グループ(EIB)は、100億ユーロ(117億ドル)の新規融資を承認したと木曜日に発表した。このうち約20億ユーロは、欧州のクリーンエネルギーへの移行を加速させ、エネルギー安全保障を強化するためのものだ。 この資金には、ドイツの洋上風力発電プロジェクト、イタリアの太陽光発電、オーストリアの企業による再生可能エネルギー導入への支援に加え、ラトビアの暖房効率改善やオランダの電力網容量拡大への投資も含まれる。 EIBは、ウクライナ紛争と中東情勢の混乱により、欧州がエネルギー供給の混乱に直面している中で、今回の融資が行われたと述べた。 EIBグループのナディア・カルヴィーノ総裁は、ウクライナと中東で続く紛争が示すように、欧州は化石燃料への依存から脱却する必要があると述べた。 この資金調達は、欧州委員会が2026年3月に発表した「クリーンエネルギー投資戦略」や、今週発表された「AccelerateEU」計画など、化石燃料からの脱却を加速させることを目的としたクリーンエネルギー政策に沿ったものである。

Related Articles

Treasury

Scotiabank Previews This Week's February and Preliminary March GDP for Canada

Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.

$$CXY
Australia

Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing

Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%

$VICR
Australia

BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%

$BMRN$FOLD